Abcam to acquire biovision for $340 million

Cambridge, united kingdom, aug. 02, 2021 (globe newswire) -- abcam plc (aim lse: abc; nasdaq: abcm) ("abcam", “the company” or "the group"), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire biovision, inc. ("biovision"), a wholly owned subsidiary of boai nky medical holdings ltd. (“nky”), for $340 million (the “acquisition”).
ABCM Ratings Summary
ABCM Quant Ranking